LQ3

LQ3 is an orally bioavailable small molecule inhibitor of the Transforming Growth Factor-beta type I receptor (TGFβR1), specifically targeting Activin receptor-like kinase 5 (ALK5). Developed by Sichuan Yiaso Pharmaceutical Technology, the drug is primarily being investigated for the treatment of idiopathic pulmonary fibrosis (IPF). The TGF-β signaling pathway is a critical mediator of tissue fibrosis, promoting the differentiation of fibroblasts into myofibroblasts and the excessive production of extracellular matrix proteins. By selectively inhibiting ALK5, LQ3 aims to halt or reverse the progression of pulmonary fibrosis. As of early 2024, the candidate is undergoing Phase 1 clinical evaluation in China to assess its safety, tolerability, and pharmacokinetics in both healthy volunteers and patients with IPF.